These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27640331)

  • 41. The natural history of PBC: has it changed?
    Lee YM; Kaplan MM
    Semin Liver Dis; 2005 Aug; 25(3):321-6. PubMed ID: 16143947
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate.
    Lee YM; Kaplan MM
    Am J Gastroenterol; 2003 Jan; 98(1):205-8. PubMed ID: 12526960
    [TBL] [Abstract][Full Text] [Related]  

  • 43. How the concept of biochemical response influenced the management of primary biliary cholangitis over time.
    Lammers WJ; Leeman M; Ponsioen CI; Boonstra K; van Erpecum KJ; Wolfhagen FH; Kuyvenhoven JP; Vrolijk JM; Drenth JP; Witteman EM; van Nieuwkerk CM; van der Spek BW; Witteman BJ; Erkelens GW; Verhagen MA; van Tuyl SA; Poen AC; Brouwer JT; Ter Borg F; Koek GH; van Ditzhuijsen TJ; Hansen BE;
    Neth J Med; 2016 Jul; 74(6):240-6. PubMed ID: 27571721
    [TBL] [Abstract][Full Text] [Related]  

  • 44. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid.
    Myers RP; Swain MG; Lee SS; Shaheen AA; Burak KW
    Am J Gastroenterol; 2013 Jun; 108(6):933-41. PubMed ID: 23649186
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy.
    Tang R; Wei Y; Li Y; Chen W; Chen H; Wang Q; Yang F; Miao Q; Xiao X; Zhang H; Lian M; Jiang X; Zhang J; Cao Q; Fan Z; Wu M; Qiu D; Fang JY; Ansari A; Gershwin ME; Ma X
    Gut; 2018 Mar; 67(3):534-541. PubMed ID: 28213609
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
    Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
    Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid.
    Angulo P; Lindor KD; Therneau TM; Jorgensen RA; Malinchoc M; Kamath PS; Dickson ER
    Liver; 1999 Apr; 19(2):115-21. PubMed ID: 10220741
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival.
    Al-Chalabi T; Portmann BC; Bernal W; McFarlane IG; Heneghan MA
    Aliment Pharmacol Ther; 2008 Jul; 28(2):209-20. PubMed ID: 18433467
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
    Angulo P; Jorgensen RA; Keach JC; Dickson ER; Smith C; Lindor KD
    Hepatology; 2000 Feb; 31(2):318-23. PubMed ID: 10655252
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort.
    Jones DE; Bhala N; Burt J; Goldblatt J; Prince M; Newton JL
    Gut; 2006 Apr; 55(4):536-41. PubMed ID: 16299032
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of depression and antidepressant usage on primary biliary cholangitis clinical outcomes.
    Shaheen AA; Kaplan GG; Almishri W; Vallerand I; Frolkis AD; Patten S; Swain MG
    PLoS One; 2018; 13(4):e0194839. PubMed ID: 29617396
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study.
    Mells GF; Pells G; Newton JL; Bathgate AJ; Burroughs AK; Heneghan MA; Neuberger JM; Day DB; Ducker SJ; Sandford RN; Alexander GJ; Jones DE;
    Hepatology; 2013 Jul; 58(1):273-83. PubMed ID: 23471852
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
    Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
    Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Investigational drugs in phase II clinical trials for primary biliary cholangitis.
    Silveira MG; Lindor KD
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1115-1121. PubMed ID: 28836457
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ursodeoxycholic acid in primary biliary cirrhosis.
    Combes B
    Semin Liver Dis; 1997 May; 17(2):125-8. PubMed ID: 9170199
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Natural History of Primary Biliary Cholangitis in the Ursodeoxycholic Acid Era: Role of Scoring Systems.
    Goel A; Kim WR
    Clin Liver Dis; 2018 Aug; 22(3):563-578. PubMed ID: 30259853
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metabolic syndrome associated with primary biliary cirrhosis.
    Floreani A; Cazzagon N; Franceschet I; Canesso F; Salmaso L; Baldo V
    J Clin Gastroenterol; 2015 Jan; 49(1):57-60. PubMed ID: 24231935
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment.
    Chen J; Xue D; Gao F; Tao L; Li Y; Zhang Q; Wang R; Sun L; Yang X; Liu Y; Zhu B; Niu S; Wang X
    Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1352-1360. PubMed ID: 29889683
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An electron microscopic and morphometric study of ursodeoxycholic effect in primary biliary cirrhosis.
    Neuman MG; Cameron RG; Haber JA; Katz GG; Blendis LM
    Liver; 2002 Jun; 22(3):235-44. PubMed ID: 12100574
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
    Holtmeier J; Leuschner U
    Digestion; 2001; 64(3):137-50. PubMed ID: 11786661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.